Detall de la convocatòria

Expressió d'interès - Expression of interest

Característiques

Característica
Objectiu de la convocatòria
UCB's Investigator-Initiated Studies (IISs) program supports independent research with the potential to advance medical and scientific knowledge. These studies are conceived, sponsored, and conducted by investigators without influence from UCB, and aim to generate key data relevant to a specific therapeutic area or drug, addressing questions not explored during Phase I–III development and providing practical insights to support clinicians in their day-to-day practice.
Característiques principals
Current Strategic Areas of Interest:
  • Rare diseases
    - Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), Thymidine kinase 2 deficiency (TK2d)
    - Myasthenia Gravis (MG)
  • Epilepsy
    - Developmental Epileptic Encephalopathies
    - Acute Seizure Management
    - Chronic Treatment and Overarching Themes
  • Immunology
    - Psoriatic disease (PsA)
    - Moderate to severe Psoriasis (PsO)
    - Axial spondyloarthritis (axSpA)
    - Moderate to severe Hidradenitis Suppurativa (HS)
  • Bone
    • Lloc de presentació
    HMRIB and PSMAR staff who need more information should contact:
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: [email protected] Ext.: 1670
    Marta López: [email protected] Ext.: 1576
    Convocatòria (URL)
    https://www.ucb.com/innovation/funding/investigator-initiated-studies
    Informació addicional
    Submissions are welcomed throughout the year however there will be strict review cycles (see below). If your study proposal is submitted during the one of three yearly review periods it will have to wait until the next review cycle to be evaluated.

  • Immunology / Bone
    1st cycle: 1 January – 31 January
    2nd cycle: 1 June – 30 June
    3rd cycle: 1 September – 30 September
  • Rare diseases / Epilepsy
    1st cycle: 1 February – 28 February
    2nd cycle: 1 July – 31 July
    3rd cycle: 1 October – 30 October
    • Requisits
  • Studies must have scientific merit, align with UCB’s areas of interest, be well-designed, and meet ethical and regulatory requirements.
  • Eligible study types include interventional and non-interventional clinical studies, non/pre-clinical studies, HEOR and population health research, non-product-related studies, and patient registry-based studies.
  • The proposal must be led by an investigator with the necessary qualifications and experience to conduct the proposed study, and they must be supported by a team capable of carrying out all stages of the study.

    • Arxius

    Arxiu